Paratek Pharmaceuticals

Company Snapshot: Paratek Pharmaceuticals

Last Change Volume High Low

Company Overview

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.

Client News

  1. Mar 5 2024 Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract
  2. Jan 16 2024 Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer
  3. Dec 13 2023 Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
  4. Oct 5 2023 Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023